Search research articles
Contact Us
Filters
Showing results (41-50 of 53) with videos related to
Page
of 6
Sort By:
Mayo Clinic Proceedings
|
January 8, 2014
The increasing incidence of young-onset colorectal cancer: a call to action
Dennis J Ahnen, Sally W Wade, Whitney F Jones, et al.
Leukemia & Lymphoma
|
July 8, 2024
Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis
James J Wu, Sally W Wade, Taha Itani, et al.
Advances in Therapy
|
October 6, 2023
Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients
Bijal Shah, Jenny M H Chen, James J Wu, et al.
Journal of Medical Economics
|
May 25, 2022
Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England
Svenja Petersohn, Gilles Salles, Michael Wang, et al.
The Journal of Dermatological Treatment
|
October 9, 2015
Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice
Steven R Feldman, Donald M Bushnell, Paul A Klekotka, et al.
Applied Health Economics and Health Policy
|
April 19, 2012
Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy
Hema N Viswanathan, Jeffrey R Curtis, Jingbo Yu, et al.
Bone
|
January 17, 2012
Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan
Sally W Wade, Jeffrey R Curtis, Jingbo Yu, et al.
Rheumatology Advances in Practice
|
November 26, 2019
Tumour necrosis factor inhibitor exposure and radiographic outcomes in Veterans with rheumatoid arthritis: a longitudinal cohort study
Grant W Cannon, Alan R Erickson, Chia-Chen Teng, et al.
Advances in Therapy
|
March 18, 2024
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor
Gilles Salles, Jenny M H Chen, Ina Zhang, et al.
Expert Review of Anticancer Therapy
|
February 1, 2023
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
M Lia Palomba, Paola Ghione, Anik R Patel, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 53) with videos related to
Sort By:
Page
of 6
Mayo Clinic Proceedings
|
January 8, 2014
The increasing incidence of young-onset colorectal cancer: a call to action
Dennis J Ahnen, Sally W Wade, Whitney F Jones, et al.
Leukemia & Lymphoma
|
July 8, 2024
Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis
James J Wu, Sally W Wade, Taha Itani, et al.
Advances in Therapy
|
October 6, 2023
Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients
Bijal Shah, Jenny M H Chen, James J Wu, et al.
Journal of Medical Economics
|
May 25, 2022
Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England
Svenja Petersohn, Gilles Salles, Michael Wang, et al.
The Journal of Dermatological Treatment
|
October 9, 2015
Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice
Steven R Feldman, Donald M Bushnell, Paul A Klekotka, et al.
Applied Health Economics and Health Policy
|
April 19, 2012
Direct healthcare costs of osteoporosis-related fractures in managed care patients receiving pharmacological osteoporosis therapy
Hema N Viswanathan, Jeffrey R Curtis, Jingbo Yu, et al.
Bone
|
January 17, 2012
Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan
Sally W Wade, Jeffrey R Curtis, Jingbo Yu, et al.
Rheumatology Advances in Practice
|
November 26, 2019
Tumour necrosis factor inhibitor exposure and radiographic outcomes in Veterans with rheumatoid arthritis: a longitudinal cohort study
Grant W Cannon, Alan R Erickson, Chia-Chen Teng, et al.
Advances in Therapy
|
March 18, 2024
Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell Lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor
Gilles Salles, Jenny M H Chen, Ina Zhang, et al.
Expert Review of Anticancer Therapy
|
February 1, 2023
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
M Lia Palomba, Paola Ghione, Anik R Patel, et al.
Page
of 6